Skip to main content
OpenTrials
Completed

NCT Number: NCT01258205

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease (CD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

QPharm Pty Limited, Herston, Queensland, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Part A - Healthy Subjects:

  • Healthy male or female of non-reproductive potential subjects between 18 to 45 years-of-age
  • Body mass index (BMI) between 18 and 32 kg/m2
  • Normal or clinically acceptable physical examination, clinical laboratory values, and ECG
  • Additional inclusion criteria apply

Part B - Crohn's Subjects:

  • Male or female subjects with CD between 18 to 55 years-of-age
  • Body mass index (BMI) between 18 and 32 kg/m2
  • Normal or clinically acceptable physical examination (PE), clinical laboratory values, and ECG; clinically acceptable PE includes evidence of mild to severe CD
  • Diagnosis of ileal or ileo-colonic CD for a minimum of 6 months
  • Mild to severe CD defined by a Crohn's Disease Activity Index (CDAI) score equal to or greater than 180 and equal to or less than 450
  • Elevated fecal calprotectin and CRP
  • Additional inclusion criteria apply

Exclusion criteria

Parts A - Healthy Subjects:

  • History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;
  • Recent or on-going infection(s)
  • Underlying condition(s) that predisposes the subject to infections
  • History of malignancy of any type
  • Additional exclusion criteria apply

Part B only - Crohn's Subjects:

  • History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;
  • Recent or on-going infection(s)
  • Underlying condition(s) that predisposes the subject to infections
  • History of malignancy of any type
  • Additional exclusion criteria apply

Treatment and study plan

AMG 139

Drug

Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).

Primary outcomes

  1. Safety & tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139

    Time frame: 36 weeks

Secondary outcomes

  1. Characterization of the pharmacokinetic (PK) parameters (AUCtau, Cmax, tmax) for AMG 139 after multiple IV and SC dose administrations in healthy subjects and subjects with mild to severe CD

    Time frame: 36 weeks

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease, and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Dec 10, 2010
Registry last updated
May 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.